Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 3/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30093198 | 0.86 | PYCR1 (0.67) | PYCR1TAAR1AOC3RIPK1KMT2A | |
| SCHEMBL3191532 | 0.86 | PYCR1 (0.67) | PYCR1TAAR1AOC3RIPK1KMT2A | |
| SCHEMBL3240150 | 0.81 | PYCR1 (0.56) | PYCR1TAAR1AOC3RIPK1KMT2A | |
| SCHEMBL11181366 | 0.80 | PYCR1 (0.57) | PYCR1TAAR1KMT2AMEN1LMNA | |
| SCHEMBL171946 | 0.80 | PYCR1 (0.60) | PYCR1TAAR1AOC3RIPK1KMT2A | |
| SCHEMBL22304838 | 0.80 | PYCR1 (0.60) | PYCR1TAAR1AOC3RIPK1KMT2A | |
| SCHEMBL10814136 | 0.78 | PYCR1 (0.63) | PYCR1TAAR1KMT2ACXCR3MEN1 | |
| SCHEMBL21268450 | 0.78 | ALDH1A1 (0.63) | PYCR1KMT2ANPC1MEN1RAB9A | |
| SCHEMBL13232509 | 0.78 | PYCR1 (0.58) | PYCR1TAAR1AOC3KMT2ANPC1 | |
| SCHEMBL10663042 | 0.78 | PYCR1 (0.58) | PYCR1AOC3KMT2ACXCR3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1436077-A | stable pharmaceutical composition containing calcium blocker | SANKYO CO (JP) | 2003-08-13 | — | — | CN | claimed |
| US-20030073670-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2003-04-17 | — | — | US | claimed |
| EP-1285655-A1 | STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING CALCIUM CHANNEL BLOCKERS | Sankyo Company, Limited (JP) | 2003-02-26 | — | — | EP | claimed |
| US-20100144696-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100144697-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
| CN-100450483-C | stable pharmaceutical composition containing calcium blocker | SANKYO CO (JP) | 2009-01-14 | — | — | CN | disclosed |
| US-20070142442-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2007-06-21 | — | — | US | disclosed |
| CN-1436077-A | stable pharmaceutical composition containing calcium blocker | SANKYO CO (JP) | 2003-08-13 | — | — | CN | disclosed |
| US-20030073670-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2003-04-17 | — | — | US | disclosed |
| EP-1285655-A1 | STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING CALCIUM CHANNEL BLOCKERS | Sankyo Company, Limited (JP) | 2003-02-26 | — | — | EP | disclosed |
| CN-1031531-A | 1,4-dihydropyridine its preparation method and be used for the purposes of medicine | DELAGRANGE LAB (ES) | 1989-03-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144696-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1C, CACNA1S, CACNA1B | PYCR1 1945/4885TAAR1 1844/4885AOC3 1551/4885 |
| US-20100144697-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1C, CACNA1S, CACNA1B | PYCR1 1945/4885TAAR1 1844/4885AOC3 1551/4885 |
| US-20070142442-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1C, CACNA1S, CACNA1B | PYCR1 1945/4885TAAR1 1844/4885AOC3 1551/4885 |
| US-20030073670-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1S, CACNA1C, CACNA1D | PYCR1 1858/4885TAAR1 1697/4885AOC3 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.